Brokerages Set Femasys Inc. (NASDAQ:FEMY) PT at $5.50

Femasys Inc. (NASDAQ:FEMY) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $5.50.

Several research firms recently issued reports on FEMY. Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a research note on Thursday, January 22nd. Lake Street Capital began coverage on shares of Femasys in a research report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price objective for the company. Finally, Wall Street Zen cut shares of Femasys from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Hedge Funds Weigh In On Femasys

A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp raised its position in Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after acquiring an additional 24,500 shares during the period. Kovack Advisors Inc. acquired a new position in Femasys during the fourth quarter worth $27,000. Osaic Holdings Inc. acquired a new position in Femasys during the second quarter worth $45,000. HRT Financial LP purchased a new stake in shares of Femasys during the fourth quarter worth $30,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Femasys during the fourth quarter worth $36,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Stock Performance

FEMY opened at $0.41 on Wednesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 4.53 and a quick ratio of 2.95. The firm has a fifty day moving average price of $0.49 and a 200 day moving average price of $0.63. Femasys has a 1 year low of $0.31 and a 1 year high of $1.26. The stock has a market cap of $24.58 million, a P/E ratio of -0.81 and a beta of -2.28.

Femasys (NASDAQ:FEMY) last posted its earnings results on Tuesday, March 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.07. Femasys had a negative net margin of 812.74% and a negative return on equity of 534.94%. The firm had revenue of $0.81 million during the quarter, compared to analysts’ expectations of $1.06 million.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.